The problem
Poor demand visibility of key malaria commodities can lead to unhealthy markets with interrupted, limited supply and volatile product prices. To inform decisions and ensure people in need have access to core tools, policymakers and market participants such as manufacturers, distributers and farmers need up-to-date commodity forecasts for artemisinin-based combination therapies (ACTs), artemisinin and rapid diagnostic tests.
Our response
Unitaid and the Malaria Forecasting Consortium produced a series of detailed market projections about the size and trends in the global markets for the commodities needed to manage malaria until 2021. These reports ensured reliable and timely information was collected and communicated to all actors in the supply chain.
Downloads
Our partners
These forecasts were carried out by the Malaria Diagnostic and Artemisinin Treatment Commodities Forecasting Consortium, led by the Clinton Health Access Initiative (CHAI), and overseen by a Steering Committee composed of representatives from Unitaid, the President’s Malaria Initiative, the World Health Organization, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Medicines for Malaria Venture.
